The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Isabel Drake

Isabel Drake

Associate professor

Isabel Drake

Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition


  • Abhijit Sen
  • Nikos Papadimitriou
  • Pagona Lagiou
  • Aurora Perez-Cornago
  • Ruth C. Travis
  • Timothy J. Key
  • Neil Murphy
  • Marc Gunter
  • Heinz Freisling
  • Ioanna Tzoulaki
  • David C. Muller
  • Amanda J. Cross
  • David S. Lopez
  • Manuela Bergmann
  • Heiner Boeing
  • Christina Bamia
  • Anastasia Kotanidou
  • Anna Karakatsani
  • Anne Tjønneland
  • Cecilie Kyrø
  • Malene Outzen
  • María Luisa Redondo
  • Valerie Cayssials
  • Maria Dolores Chirlaque
  • Aurelio Barricarte
  • Maria Jose Sánchez
  • Nerea Larrañaga
  • Rosario Tumino
  • Sara Grioni
  • Domenico Palli
  • Saverio Caini
  • Carlotta Sacerdote
  • Bas Bueno-de-Mesquita
  • Tilman Kühn
  • Rudolf Kaaks
  • Lena Maria Nilsson
  • Rikard Landberg
  • Peter Wallström
  • Isabel Drake
  • Bodil Hammer Bech
  • Kim Overvad
  • Dagfinn Aune
  • Kay Tee Khaw
  • Elio Riboli
  • Dimitrios Trichopoulos
  • Antonia Trichopoulou
  • Konstantinos K. Tsilidis

Summary, in English

The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94–1.09) and 0.98 (95% CI, 0.90–1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79–1.21) and 0.89 (95% CI, 0.70–1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.


  • Nutrition Epidemiology
  • EpiHealth: Epidemiology for Health
  • Diabetes - Cardiovascular Disease
  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year







International Journal of Cancer





Document type

Journal article


John Wiley & Sons Inc.


  • Cancer and Oncology
  • Nutrition and Dietetics


  • caffeinated
  • coffee
  • decaffeinated
  • EPIC
  • prostate cancer
  • tea



Research group

  • Nutrition Epidemiology
  • Diabetes - Cardiovascular Disease


  • ISSN: 0020-7136